Edwin is a serial entrepreneur and value creator in European life science companies. As CEO, he built two businesses (Oxford Asymmetry International plc and Ablynx nv), led their successful IPOs on the LSE, EuroNext and NASDAQ and raised over >USD550M in equity and debt financing. Edwin was responsible for the sale of both companies generating values of GBP316million and USD4.8 billion respectively. At Ablynx, he oversaw the whole process from discovery to approval and preparation for the launch of Cablivi™ - a product designed to treat an ultra-rare hematological disease. Edwin has over 30 years of international Board level experience in more than 20 companies, mostly as Chairman. With such broad and deep expertise across the lifescience sector, Edwin currently focuses on a small, high quality portfolio of Chairman/NED roles in both public and private life science companies with potentially breakthrough products/technologies. Currently he is Chairman of Avantium NV, LabGenius Therapeutics Ltd, NanoSyrinx Ltd and Greywolf Therapeutics Ltd. Until December 2025, he was Chairman of Dark Blue Therapeutics Ltd which was sold to Amgen for up to $840M.